Table 4 Bivariate analysis

Hospital centers

 FJD

1

–

–

 HCSC

0.99

0.66–1.48

0.9

 Others

0.91

0.46–1.08

0.78

HiLe

HIS

HPH

HUG

HULP

Gender, male

0.92

0.62–1.35

0.6

Age in years

 ≤ 60

1

–

–

 60–69

1.18

0.77–1.80

0.4

 70–79

1.29

0.72–2.3

0.28

 ≥ 80

0.75

0.41–1.38

0.36

Active-former smoker

0.77

0.52–1.11

0.2

Year of ILD diagnosis (5 year intervals)

 2007–11

1

–

–

 2012–16

1.53

0.78–3.01

0.2

 2017–20

2.54

1.1–5.54

0.018

Comorbidity (Yes vs No)

CV disease

1.19

0.82–1.72

0.3

Non CV disease

0.76

0.48–1.19

0.23

ILD associated fibrosis (HRTC) (n = 

1.13

0.75–1.70

0.5

ILD associated emphysema (HRTC)

0.7

0.35–1.37

0.3

ILD associated pulmonary (HRTC) hypertension

1.04

0.56–1.93

0.8

Radiological ILD pattern

 NSIP

1

–

–

 UIP

1.75

1.18–2.6

0.005

 Others

1.12

0.7–1.81

0.6

FVC% ≥ 80

0.94

0.64–1.37

0.7

DLCO% ≥ 60

0.91

0.63–1.32

0.6

ERS

1.0

0.99–1.01

0.5

Glucocorticoids

0.98

0.71–1.36

0.9

DMARDs (specific DMARD vs others)

 Conventional synthetic DMARDs

  MTX-LEF-AM

1.17

0.68–1.99

0.5

  AZA-MMF

1.23

0.82–1.84

0.3

  Cyclosporin-Tacrolimus

0.63

0.36–1.11

0.1

 Biologic agents (RTX)

1.15

0.57–2.3

0.6

Antifibrotics agents

1.07

0.49–2.32

0.8

O₂ during follow-up

1.39

0.96–2.02

0.07

Rheumatoid Factor + (≥ 40)

0.85

0.49–1.45

0.58

ANA antibodies + (≥ 1/320)

1.71

0.96–3.04

0.065

Ro antibodies + 

0.59

0.39–0.88

0.01